๐Ÿ”ฌDeep Research

ARAY โ€” Accuray Inc ยท catalysts, narrative & risks

ยท22 sourcesARAY forecast โ†’

Overview (point-in-time: as of Oct 2โ€“4, 2026)

Accuray (NASDAQ: ARAY) is a radiation-therapy company whose products center on the CyberKnife and TomoTherapy platforms (including the Radixact system), founded in 1990 with roughly 809 employees [1], [16]. As of the Oct 2, 2026 close, the stock traded near $0.28 (+5.16% that day), with a market capitalization of about $33.6M, ~119.4M shares outstanding, and a 52-week range of $0.22โ€“$2.10 [16], [17]. The stock has been in a steep downtrend: approximately -65.7% year-to-date and roughly -83% over the past year relative to the S&P 500 [14], [17].

Recent catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’